FANCD2 and breast cancer: To provide functional evidence that STAT3 inhibition is sufficient to render cells deficient in FA pathway activity, we tested the melphalan sensitivity of breast cancer cells invalidated for STAT3 expression versus cells invalidated for FANCD2 expression (Supplementary Fig. 4E).